MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, MCL1 inhibition did not enhance the anticlonogenic effect of imatinib on normal hematopoietic stem/progenitor cells, suggesting a therapeutic window for an MCL1 inhibitor and TKI combination treatment specifically targeting CML cells.